Regulation of β2-adrenergic receptor function by conformationally selective single-domain intrabodies

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Regulation of β2-adrenergic receptor function by conformationally selective single-domain intrabodies. / Staus, Dean P; Wingler, Laura M; Strachan, Ryan T; Rasmussen, Søren Gøgsig Faarup; Pardon, Els; Ahn, Seungkirl; Steyaert, Jan; Kobilka, Brian K; Lefkowitz, Robert J.

In: Molecular Pharmacology, Vol. 85, No. 3, 03.2014, p. 472-81.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Staus, DP, Wingler, LM, Strachan, RT, Rasmussen, SGF, Pardon, E, Ahn, S, Steyaert, J, Kobilka, BK & Lefkowitz, RJ 2014, 'Regulation of β2-adrenergic receptor function by conformationally selective single-domain intrabodies', Molecular Pharmacology, vol. 85, no. 3, pp. 472-81. https://doi.org/10.1124/mol.113.089516

APA

Staus, D. P., Wingler, L. M., Strachan, R. T., Rasmussen, S. G. F., Pardon, E., Ahn, S., Steyaert, J., Kobilka, B. K., & Lefkowitz, R. J. (2014). Regulation of β2-adrenergic receptor function by conformationally selective single-domain intrabodies. Molecular Pharmacology, 85(3), 472-81. https://doi.org/10.1124/mol.113.089516

Vancouver

Staus DP, Wingler LM, Strachan RT, Rasmussen SGF, Pardon E, Ahn S et al. Regulation of β2-adrenergic receptor function by conformationally selective single-domain intrabodies. Molecular Pharmacology. 2014 Mar;85(3):472-81. https://doi.org/10.1124/mol.113.089516

Author

Staus, Dean P ; Wingler, Laura M ; Strachan, Ryan T ; Rasmussen, Søren Gøgsig Faarup ; Pardon, Els ; Ahn, Seungkirl ; Steyaert, Jan ; Kobilka, Brian K ; Lefkowitz, Robert J. / Regulation of β2-adrenergic receptor function by conformationally selective single-domain intrabodies. In: Molecular Pharmacology. 2014 ; Vol. 85, No. 3. pp. 472-81.

Bibtex

@article{4b7a26436e5b4c17974ff10ea684bc96,
title = "Regulation of β2-adrenergic receptor function by conformationally selective single-domain intrabodies",
abstract = "The biologic activity induced by ligand binding to orthosteric or allosteric sites on a G protein-coupled receptor (GPCR) is mediated by stabilization of specific receptor conformations. In the case of the β2 adrenergic receptor, these ligands are generally small-molecule agonists or antagonists. However, a monomeric single-domain antibody (nanobody) from the Camelid family was recently found to allosterically bind and stabilize an active conformation of the β2-adrenergic receptor (β2AR). Here, we set out to study the functional interaction of 18 related nanobodies with the β2AR to investigate their roles as novel tools for studying GPCR biology. Our studies revealed several sequence-related nanobody families with preferences for active (agonist-occupied) or inactive (antagonist-occupied) receptors. Flow cytometry analysis indicates that all nanobodies bind to epitopes displayed on the intracellular receptor surface; therefore, we transiently expressed them intracellularly as {"}intrabodies{"} to test their effects on β2AR-dependent signaling. Conformational specificity was preserved after intrabody conversion as demonstrated by the ability for the intracellularly expressed nanobodies to selectively bind agonist- or antagonist-occupied receptors. When expressed as intrabodies, they inhibited G protein activation (cyclic AMP accumulation), G protein-coupled receptor kinase (GRK)-mediated receptor phosphorylation, β-arrestin recruitment, and receptor internalization to varying extents. These functional effects were likely due to either steric blockade of downstream effector (Gs, β-arrestin, GRK) interactions or stabilization of specific receptor conformations which do not support effector coupling. Together, these findings strongly implicate nanobody-derived intrabodies as novel tools to study GPCR biology.",
keywords = "Amino Acid Sequence, Cell Line, Cyclic AMP, G-Protein-Coupled Receptor Kinases, HEK293 Cells, Humans, Molecular Sequence Data, Phosphorylation, Protein Binding, Receptors, Adrenergic, beta-2, Receptors, G-Protein-Coupled, Sequence Alignment, Single-Domain Antibodies",
author = "Staus, {Dean P} and Wingler, {Laura M} and Strachan, {Ryan T} and Rasmussen, {S{\o}ren G{\o}gsig Faarup} and Els Pardon and Seungkirl Ahn and Jan Steyaert and Kobilka, {Brian K} and Lefkowitz, {Robert J}",
year = "2014",
month = mar,
doi = "10.1124/mol.113.089516",
language = "English",
volume = "85",
pages = "472--81",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

RIS

TY - JOUR

T1 - Regulation of β2-adrenergic receptor function by conformationally selective single-domain intrabodies

AU - Staus, Dean P

AU - Wingler, Laura M

AU - Strachan, Ryan T

AU - Rasmussen, Søren Gøgsig Faarup

AU - Pardon, Els

AU - Ahn, Seungkirl

AU - Steyaert, Jan

AU - Kobilka, Brian K

AU - Lefkowitz, Robert J

PY - 2014/3

Y1 - 2014/3

N2 - The biologic activity induced by ligand binding to orthosteric or allosteric sites on a G protein-coupled receptor (GPCR) is mediated by stabilization of specific receptor conformations. In the case of the β2 adrenergic receptor, these ligands are generally small-molecule agonists or antagonists. However, a monomeric single-domain antibody (nanobody) from the Camelid family was recently found to allosterically bind and stabilize an active conformation of the β2-adrenergic receptor (β2AR). Here, we set out to study the functional interaction of 18 related nanobodies with the β2AR to investigate their roles as novel tools for studying GPCR biology. Our studies revealed several sequence-related nanobody families with preferences for active (agonist-occupied) or inactive (antagonist-occupied) receptors. Flow cytometry analysis indicates that all nanobodies bind to epitopes displayed on the intracellular receptor surface; therefore, we transiently expressed them intracellularly as "intrabodies" to test their effects on β2AR-dependent signaling. Conformational specificity was preserved after intrabody conversion as demonstrated by the ability for the intracellularly expressed nanobodies to selectively bind agonist- or antagonist-occupied receptors. When expressed as intrabodies, they inhibited G protein activation (cyclic AMP accumulation), G protein-coupled receptor kinase (GRK)-mediated receptor phosphorylation, β-arrestin recruitment, and receptor internalization to varying extents. These functional effects were likely due to either steric blockade of downstream effector (Gs, β-arrestin, GRK) interactions or stabilization of specific receptor conformations which do not support effector coupling. Together, these findings strongly implicate nanobody-derived intrabodies as novel tools to study GPCR biology.

AB - The biologic activity induced by ligand binding to orthosteric or allosteric sites on a G protein-coupled receptor (GPCR) is mediated by stabilization of specific receptor conformations. In the case of the β2 adrenergic receptor, these ligands are generally small-molecule agonists or antagonists. However, a monomeric single-domain antibody (nanobody) from the Camelid family was recently found to allosterically bind and stabilize an active conformation of the β2-adrenergic receptor (β2AR). Here, we set out to study the functional interaction of 18 related nanobodies with the β2AR to investigate their roles as novel tools for studying GPCR biology. Our studies revealed several sequence-related nanobody families with preferences for active (agonist-occupied) or inactive (antagonist-occupied) receptors. Flow cytometry analysis indicates that all nanobodies bind to epitopes displayed on the intracellular receptor surface; therefore, we transiently expressed them intracellularly as "intrabodies" to test their effects on β2AR-dependent signaling. Conformational specificity was preserved after intrabody conversion as demonstrated by the ability for the intracellularly expressed nanobodies to selectively bind agonist- or antagonist-occupied receptors. When expressed as intrabodies, they inhibited G protein activation (cyclic AMP accumulation), G protein-coupled receptor kinase (GRK)-mediated receptor phosphorylation, β-arrestin recruitment, and receptor internalization to varying extents. These functional effects were likely due to either steric blockade of downstream effector (Gs, β-arrestin, GRK) interactions or stabilization of specific receptor conformations which do not support effector coupling. Together, these findings strongly implicate nanobody-derived intrabodies as novel tools to study GPCR biology.

KW - Amino Acid Sequence

KW - Cell Line

KW - Cyclic AMP

KW - G-Protein-Coupled Receptor Kinases

KW - HEK293 Cells

KW - Humans

KW - Molecular Sequence Data

KW - Phosphorylation

KW - Protein Binding

KW - Receptors, Adrenergic, beta-2

KW - Receptors, G-Protein-Coupled

KW - Sequence Alignment

KW - Single-Domain Antibodies

U2 - 10.1124/mol.113.089516

DO - 10.1124/mol.113.089516

M3 - Journal article

C2 - 24319111

VL - 85

SP - 472

EP - 481

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 3

ER -

ID: 120587026